Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

KM 001 - Kamari Pharma

Next Previous
Drug Profile

KM 001 - Kamari Pharma

Alternative Names: KM-001 - Kamari Pharma

Latest Information Update: 16 May 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Kamari Pharma
  • Class Anti-inflammatories; Antipruritics; Calcium regulators; Keratolytics; Skin disorder therapies; Small molecules
  • Mechanism of Action TRPV3 protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Pachyonychia congenita; Palmoplantar keratoderma; Pruritus
  • Preclinical Ichthyosis

Most Recent Events

  • 08 May 2025 Adverse events and efficacy data from a phase-Ib trial in Pachyonychia congenita and Palmoplantar keratoderma released by Kamari Pharma
  • 07 Nov 2024 Kamari Pharma completes phase-I trial in Pachyonychia congenita and Palmoplantar keratoderma (In adults, In the elderly) in United Kingdom (Topical) (ISRCTN67285394) (NCT05956314)
  • 05 Sep 2024 Kamari Pharma completes a phase-I clinical trial in Palmoplantar keratoderma and Pachyonychia congenita in Israel (NCT05435638)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top